Antibody-Drug Conjugates: Recent Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (20 July 2023) | Viewed by 357
Special Issue Editors
2. UMR1100 CEPR INSERM Université de Tours, Team Proteolytic mechanisms in inflammation, UFR de Médecine, 10 Bd Tonnellé, CEDEX, 37032 Tours, France
Interests: medicinal chemistry; targeted therapies; antibody–drug conjugates; heterocyclic kinase inhibitors; anticancer drugs
Special Issues, Collections and Topics in MDPI journals
2. UMR1100 CEPR INSERM Université de Tours, Team Proteolytic mechanisms in inflammation, UFR de Médecine, 10 Bd Tonnellé, CEDEX, 37032 Tours, France
Interests: antibody–drug conjugates; bioconjugation; chemical biology; chemistry; breast cancer; anticancer drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The design of innovative anticancer chemotherapies with superior antitumor efficacy and reduced toxicity continues to be a challenging endeavor. More than a century ago, Paul Ehrlich, who won the Nobel Price in Medicine in 1908, came up with an original concept known as “the magic bullet”. His vision was to link a cytotoxic payload to an entity with selective affinity for a tumor, with the aim of achieving the selective delivery of chemotherapeutic agents in the tumor environment and reducing systemic toxicity. Although this concept seems to be quite simple, its fine-tuning is fairly elaborate and still challenging today. Antibody–drug conjugates (ADCs) appear to be the ideal embodiment of Paul Ehrlich’s “magic bullet” vision—the combination of a potent cytotoxic agent (drug) with a therapeutic monoclonal antibody (mAb) via a suitably constructed spacer arm (linker). An ADC (or armed antibody) is thus a vectorized chemotherapy, harnessing both the high potency of the drug against the malignancy and the high specificity of the mAb for its target.
Particularly in the last decade, the ADC field of research has experienced a surge of interest, exploring various ADC features from the drug, its mechanism of action, its release mechanism, to the hydrophilic nature or the (site-specific) conjugation abilities of the linker, and the target or the format of the antibody. Currently, there are around 80 ADCs in clinical development, and even more in preclinical studies. With a wave of recent approvals by the FDA in the past three years, there are now 12 ADCs successfully implemented in the clinic.
This Special Issue of Pharmaceuticals aims to collect contributions on recent trends and advances in the field of ADCs, specifically addressing novel strategies in bioconjugation, cancer therapy, targeting, mechanisms of release, payload mechanism, or antibody formats. We solicit contributions, research papers or reviews on all topics connected to this research area, including, but not limited to:
- Design, synthesis, analysis, and biological evaluations of antibody–drug conjugates, protein–drug conjugates, small molecule–drug conjugates or radioimmunoconjugates;
- New bioconjugation methods;
- New mechanisms of action;
- New conjugate formats;
- New strategies to overcome resistance;
- Case studies on recently FDA-approved ADCs (e.g., Enhertu®, Trodelvy® or Zynlonta®).
Recently, their recent advances have made antibody–drug conjugates (ADCs) serious contenders to reach the envied status of Paul Ehrlich's “magic bullet”. New strategies in development are promising a bright future for this exciting area of research.
Dr. Caroline Denevault-Sabourin
Dr. Nicolas Joubert
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugates
- protein-drug conjugates
- small molecule–drug conjugates
- targeted delivery
- controlled release
- cancer research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
